Xenon Reports Positive Phase 1 Results for Pain Drugs XEN1701 and XEN1120
Bitget2026/10/29 12:32- Xenon Pharmaceuticals plans Phase 2 acute pain studies of XEN1701 and XEN1120 in the first half of 2027 following positive Phase 1 results.
- XEN1701 achieved modeled NaV1.7 receptor occupancy above 75% in peripheral and central nervous systems, without consistent autonomic cardiovascular effects.
- XEN1120 exceeded predicted effective exposures from animal models; modeling supported sustained target concentrations with maintenance dosing.
- Both drugs were generally well tolerated, with no treatment-related, dose-limiting adverse events or adverse events leading to discontinuation.
- A compound comparable to XEN1701 reduced evoked pain by approximately 85%-100% at the two highest doses in monkeys, without meaningful cardiovascular changes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Crypto prices
More
